Core Insights - Quantum BioPharma Ltd. has received two final reports related to its drug candidate Lucid-MS for Multiple Sclerosis, marking a significant milestone in its development process [1][2] - The reports will support the company's Investigational New Drug (IND) application to the US FDA for a Phase 2 clinical trial [1][2] - Lucid-MS is positioned as a first-in-class treatment targeting demyelination in Multiple Sclerosis [2] Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders [3] - The company’s lead compound, Lucid-MS, is a patented new chemical entity that has shown potential in preventing and reversing myelin degradation in preclinical models [3] - Quantum BioPharma retains a 20.10% ownership stake in Unbuzzd Wellness Inc., which is involved in the OTC version of its product unbuzzd™ [3] Financial and Strategic Aspects - The agreement with Unbuzzd Wellness Inc. includes a royalty structure of 7% on sales until total payments reach $250 million, after which the royalty will decrease to 3% indefinitely [3] - Quantum BioPharma maintains a portfolio of strategic investments through its subsidiary, FSD Strategic Investments Inc., which includes loans secured by residential or commercial property [3]